Neoplasms

All Conditions

Digestive System Diseases

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Rare Diseases

Carcinoma

Carcinoma, Hepatocellular

Adenocarcinoma

Carcinoma, Renal Cell

Liver Neoplasms

Kidney Neoplasms

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Liver Diseases

Urologic Neoplasms

Urogenital Neoplasms

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Kidney Diseases

Urologic Diseases

Male Urogenital Diseases

Renal Cell Carcinoma

Hematinics

All Drugs and Chemicals

Herbal and Botanical

Liver Extracts

Cola

Patient with clear cell kidney carcinoma more than 4 cm surgically removed

Patient with advanced hepatocellular carcinoma : biopsy or resected BCLC (Barcelona Clinic Liver Cancer) stage B or C for diagnostic and/or therapeutic purposes

Pierre Laurent-Puig, MD, PhD

Eric Tartour, MD, PhD

Jean-Charles Nault, MD

Jessica Zucman-Rossi, MD, PhD

Michael Peyromaure, MD, PhD

Jérôme Alexandre, MD, PhD

Stéphane Oudard, MD, PhD

Julien Taïeb, MD, PhD

Over the last 10 years, technological advances in molecular biology enabled a more accurate genomic characterization of tumors. For each tumor location, this led to the identification of subgroups with similar molecular characteristics. This identification allowed the development of targeted therapies and thus to improve the patient prognosis. This molecular characterization has also revealed the tumor heterogeneity. It may be the cause of treatment resistance and therefore of relapses. Additionally, tumor cells are in constant dialogue with their microenvironment composed of different immune or non immune cells. This microenvironment is now targeted in cancer treatment.

To date, there are few studies that combine a deep genomic characterization of both tumor and tumor microenvironment of the patient. Combining the two types of studies on the same tumor should help to define new therapeutic targets and should allow a combination of targeted and immunomodulatory therapies. To this end, our project is to conduct an exhaustive integrated exploratory analysis at genomic, transcriptomic and immunological levels of 3 tumor types (in colon, kidney and liver cancer).

The design consists in recruiting 50 patients per tumor location (colon, kidney, liver). For colorectal and kidney cancers, a prospective enrollment will be done for patients who have consented to the study. A retrospective enrollment will be done for patients with liver cancer only and who have consented to a national biological resource center form with genetic study approval.

The tumor samples will be taken during surgery. Blood and tumors samples will be taken as part of the treatment.

In case of a accidental germline discovery a management by a genetic consulting will be proposed.

blood samples, urine collection, tumor sample and tumor microenvironment sample

Exhaustive Genetic and Immunological Characterization of Colon, Kidney and Liver Tumors

Exhaustive Genetic and Immunological Characterization of Colon, Kidney and Liver Tumors to Define Potential Targets of Targeted and/or Immunomodulatory Therapies

The IPD (individual participant data) will not be shared. To protect confidentiality and integrity of patient information, only investigators of the study will have a regulated access to data with authorizations.

Prediction of neoantigens implicated in the intratumoral immune response

Immunologic characteristic of circulating cells

Expression profile of immune gene in urine

Assistance Publique - Hôpitaux de Paris

European Georges Pompidou Hospital

MD, PhD

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Exhaustive Genetic and Immunological Characterization of Colon, Kidney and Liver Tumors	NCT03149523	Colorectal Aden... Hepatic Carcino... Kidney Adenocar...		18 Years - 80 Years	European Georges Pompidou Hospital
Exhaustive Genetic and Immunological Characterization of Colon, Kidney and Liver Tumors	NCT03149523	Colorectal Aden... Hepatic Carcino... Kidney Adenocar...		18 Years - 80 Years	European Georges Pompidou Hospital

Spots Global Cancer Trial Database for immunological tumor microenvironment